Bms-986278 phase 2
WebMar 28, 2024 · The purpose of this study is to evaluate the drug levels, safety, and tolerability of BMS-986278 in healthy Chinese participants. ... Phase. Phase 1; Contacts and Locations. This section provides the contact details for those conducting the study, and information on where this study is being conducted. WebMar 1, 2024 · In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 1 ) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). ... (BMS-986234 and BMS-986278). BMS-986020 inhibited hepatic BA efflux transporters BSEP (IC 50 1.8 μM), MRP3 (IC 50 …
Bms-986278 phase 2
Did you know?
WebBMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kb s of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. … WebDec 1, 2024 · Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive …
WebSep 28, 2024 · Specific to PF-ILD, the LPA 1 antagonist, BMS-986278, has shown promise in preclinical and phase I studies (67, 68) and is currently in phase 2 clinical trials, with … WebDec 1, 2024 · BMS-986278 is a potent antagonist that blocks LPA 1-mediated G i, G q, G 12, and β-arrestin ... Ⅰ studies showed that it was generally well-tolerated and did not pose the same risk for hepatobiliary toxicity as BMS-986020. It is currently in phase Ⅱ trials for the treatment of lung fibrosis [119]. To date, there is only one PET ...
WebMar 1, 2024 · BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA 1) antagonists that were or are being investigated for treatment of … WebIntroduction: The LPA1 receptor is implicated in IPF pathogenesis. BMS-986278 is a potent small molecule LPA1 receptor antagonist being investigated for IPF. This study …
Web• Team member of one marketed drug (Eliquis®) and two clinical compounds (one of which is BMS-986278 in Phase 2 for IPF and PF-ILD, and another compound in Phase 1 for …
WebJan 11, 2013 · Drug: BMS-986020 Drug: Placebo matching with BMS-986020: Phase 2: Study Design. Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. ... Experimental: Arm 2: BMS-986020, 600 mg twice daily BMS-986020, 600 mg tablets, by … postprandial anxietyWebMar 1, 2024 · The current Phase 2 clinical compound BMS-986278 was evaluated in several of the same investigative assays to provide further confidence regarding its clinical safety since BMS-986234 and BMS-986278 have very similar chemical structures (Fig. 1) and dissimilar structures to BMS-986020. 2. Materials and methods2.1. Test articles postprandial bloating icd-10WebA Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis - IM027-040. Updated: 3 December, 2024 ClinicalTrials.gov About This Trial; Key Eligibility Criteria ... Phase 2. Phase. Gender(s) 21+ Age Range. Active, Not Recruiting. Treatment Options Study Arms. ASSIGNED INTERVENTION ... total rewards charter flightsWebDec 4, 2024 · In mid-stage development it has the JNK1 inhibitor CC-90001, gained through the acquisition of Celgene, and the LPA1 antagonist BMS-986278. The group also has another LPA1 antagonist, BMS-986337, in phase I, and an option over Nitto Denko’s ND-L02-s0201 in IPF; the latter is a small interfering RNA targeting heat shock protein 47. postprandial arrythmiasWebThe phase 2 study design was based on information that investigators learned during the earlier phase 1 study that provided guidance on safe dosing levels. 3 The phase 1 study … post practice test freeWebOct 21, 2024 · A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis ... in their lungs.\nBMS-986278 works by helping wound healing and tissue fibrosis.\nThis study is the first evaluation of BMS-986278 in participants with … total rewards comenity bankWeb150 mg Active for Alzheimer's Disease. Phase-Based Progress Estimates. 1. Effectiveness. 1. Safety. Spaulding Clinical Research, West Bend, WI Alzheimer's Disease BMS … total rewards comenity bank sign in